Sunitinib malate

Overview

Sunitinib (marketed as Sutent by Pfizer, and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications.

Application

Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | PDGFR

Product Information

• Catalog No.: B0084-187069
• CAS No.: 341031-54-7
• Molecular Formula: C22H27FN4O2.C4H6O5
• Molecular Weight: 532.56
• Purity: >98%

Source

Original product source